Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The average price point forecasted by analysts for Amylyx Pharmaceuticals Inc. (AMLX) is $50.20, which is $16.32 above the current market price. The public float for AMLX is 49.98M, and currently, short sellers hold a 10.93% ratio of that floaft. The average trading volume of AMLX on March 17, 2023 was 892.66K shares.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
AMLX) stock’s latest price update
Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX)’s stock price has decreased by -4.52 compared to its previous closing price of 33.60. However, the company has seen a fall of -3.26% in its stock price over the last five trading days. The Wall Street Journal reported on 09/30/22 that Amylyx Prices Newly Approved ALS Drug at $12,500 a Month
AMLX’s Market Performance
Amylyx Pharmaceuticals Inc. (AMLX) has seen a -3.26% fall in stock performance for the week, with a -8.58% decline in the past month and a -13.81% plunge in the past quarter. The volatility ratio for the week is 9.21%, and the volatility levels for the past 30 days are at 6.03% for AMLX. The simple moving average for the last 20 days is -6.81% for AMLX stock, with a simple moving average of 7.42% for the last 200 days.
Analysts’ Opinion of AMLX
Many brokerage firms have already submitted their reports for AMLX stocks, with BofA Securities repeating the rating for AMLX by listing it as a “Buy.” The predicted price for AMLX in the upcoming period, according to BofA Securities is $50 based on the research report published on January 05th of the current year 2023.
Citigroup, on the other hand, stated in their research note that they expect to see AMLX reach a price target of $21. The rating they have provided for AMLX stocks is “Buy” according to the report published on May 25th, 2022.
Goldman gave a rating of “Neutral” to AMLX, setting the target price at $10 in the report published on April 01st of the previous year.
AMLX Trading at -10.65% from the 50-Day Moving Average
After a stumble in the market that brought AMLX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -23.49% of loss for the given period.
Volatility was left at 6.03%, however, over the last 30 days, the volatility rate increased by 9.21%, as shares sank -7.76% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -10.84% lower at present.
During the last 5 trading sessions, AMLX fell by -3.26%, which changed the moving average for the period of 200-days by +265.38% in comparison to the 20-day moving average, which settled at $34.29. In addition, Amylyx Pharmaceuticals Inc. saw -13.18% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at AMLX starting from Morningside Venture Investment, who sale 150,000 shares at the price of $33.27 back on Mar 15. After this action, Morningside Venture Investment now owns 7,259,884 shares of Amylyx Pharmaceuticals Inc., valued at $4,990,997 using the latest closing price.
Morningside Venture Investment, the 10% Owner of Amylyx Pharmaceuticals Inc., sale 70,714 shares at $34.54 during a trade that took place back on Mar 14, which means that Morningside Venture Investment is holding 7,409,884 shares at $2,442,462 based on the most recent closing price.
Stock Fundamentals for AMLX
Current profitability levels for the company are sitting at:
- -29013.33 for the present operating margin
- +81.75 for the gross margin
The net margin for Amylyx Pharmaceuticals Inc. stands at -30852.98. Equity return is now at value -172.50, with -93.60 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 5.84.
In a nutshell, Amylyx Pharmaceuticals Inc. (AMLX) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.